Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
93 studies found for:    ( lymphoma [CONDITION] OR CLL [CONDITION] ) AND "ofatumumab" [TREATMENT]
Show Display Options
Rank Status Study
1 Completed
Has Results
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Ofatumumab
2 Suspended A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Idelalisib;   Drug: Ofatumumab
3 Completed
Has Results
Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)
Condition: CLL
Intervention: Drug: Ofatumumab/HDMP
4 Recruiting A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: IPI-145 (duvelisib);   Drug: Ofatumumab
5 Active, not recruiting A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: IPI-145 (duvelisib);   Drug: Ofatumumab
6 Active, not recruiting Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Ofatumumab
7 Terminated
Has Results
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Ofatumumab and Bendamustine
8 Unknown  Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Condition: Lymphoma, Mantle-Cell
Intervention: Drug: Combination of dexamethasone, ofatumumab and bendamustine
9 Withdrawn PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: ofatumumab + bendamustine
10 Completed
Has Results
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: ofatumumab + ICE;   Drug: ofatumumab + DHAP
11 Terminated Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: ofatumumab + bendamustine
12 Active, not recruiting Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: High Dose Methylprednisolone (HDMP);   Drug: Ofatumumab;   Drug: Lenalidomide
13 Active, not recruiting Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: High Dose Methylprednisolone (HDMP);   Drug: Ofatumumab;   Drug: Lenalidomide
14 Active, not recruiting
Has Results
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: ofatumumab;   Drug: ibrutinib
15 Completed Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Bendamustine;   Drug: Ofatumumab
16 Completed Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Follicular Lymphoma;   Chronic Lymphocytic Leukemia;   Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
Intervention: Drug: ofatumumab
17 Active, not recruiting A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Small Lymphocytic Lymphoma;   CLL (Chronic Lymphocytic Leukemia)
Interventions: Drug: Fludarabine Phosphate;   Biological: Ofatumumab;   Drug: Cyclophosphamide
18 Recruiting "MIRO" Molecularly Oriented Immuno-radio-therapy
Conditions: Follicular Lymphoma, Grade 1;   Follicular Lymphoma, Grade 2
Intervention: Drug: OFATUMUMAB
19 Terminated
Has Results
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Condition: Lymphoma, Non-Hodgkins
Intervention: Drug: Ofatumumab and Bortezomib
20 Active, not recruiting Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   B-Cell Non-Hodgkin's Lymphoma
Interventions: Drug: Bendamustine;   Drug: Pentostatin;   Drug: Ofatumumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.